# Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

> **NCT04156620** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 527 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04156620
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-11
- **Primary completion:** 2022-02-17
- **Final completion:** 2022-12-20
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156620, "Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04156620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*